BSG005 or placebo

Phase 1UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Fungal Infections

Conditions

Invasive Fungal Infections

Trial Timeline

Aug 23, 2021 → May 1, 2023

About BSG005 or placebo

BSG005 or placebo is a phase 1 stage product being developed by Biosergen for Invasive Fungal Infections. The current trial status is unknown. This product is registered under clinical trial identifier NCT04921254. Target conditions include Invasive Fungal Infections.

What happened to similar drugs?

10 of 20 similar drugs in Invasive Fungal Infections were approved

Approved (10) Terminated (2) Active (9)
MicafunginAstellas PharmaApproved
caspofunginMerckApproved
Ambisome + caspofunginGilead SciencesApproved
voriconazolePfizerApproved

Hype Score Breakdown

Clinical
6
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04921254Phase 1UNKNOWN

Competing Products

20 competing products in Invasive Fungal Infections

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47